Runners who complete one of the world's most challenging ultra-marathons experience less neuromuscular fatigue, muscle damage and inflammation compared to those who run distances half to one quarter as long, according to the results of research published June 26 in the open access journal PLOS ONE by Jonas Saugy and colleagues from the University of Lausanne, Switzerland.
The researchers tested the effects of sleep deprivation as well as blood and muscle markers of inflammation in runners who completed the Tor des Geants, an over 200-mile mountain ultramarathon with 24,000 m of elevation changes. Compared to participants at a shorter Alpine ultra-marathon approximately 103 miles in length, runners at Tor des Geants had fewer alterations in neuromuscular functions and lower levels of muscle damage and inflammation, despite running nearly double the distance. The authors suggest that protective pacing strategies employed by these runners in the first half of the race, combined with sleep deprivation effects in the second half may induce a relative muscle preservation process.
Citation: Saugy J, Place N, Millet GY, Degache F, Schena F, et al. (2013) Alterations of Neuromuscular Function after the World's Most Challenging Mountain Ultra-Marathon. PLoS ONE 8(6): e65596. doi:10.1371/journal.pone.0065596
Financial Disclosure: The authors have no funding or support to report.
Competing Interest Statement: The authors have declared that no competing interests exist.
PLEASE LINK TO THE SCIENTIFIC ARTICLE IN ONLINE VERSIONS OF YOUR REPORT (URL goes live after the embargo ends): http://dx.
Disclaimer: This press release refers to upcoming articles in PLOS ONE. The releases have been provided by the article authors and/or journal staff. Any opinions expressed in these are the personal views of the contributors, and do not necessarily represent the views or policies of PLOS. PLOS expressly disclaims any and all warranties and liability in connection with the information found in the release and article and your use of such information.
About PLOS ONE: PLOS ONE is the first journal of primary research from all areas of science to employ a combination of peer review and post-publication rating and commenting, to maximize the impact of every report it publishes. PLOS ONE is published by the Public Library of Science (PLOS), the open-access publisher whose goal is to make the world's scientific and medical literature a public resource.
All works published in PLOS ONE are Open Access. Everything is immediately available--to read, download, redistribute, include in databases and otherwise use--without cost to anyone, anywhere, subject only to the condition that the original authors and source are properly attributed. For more information about PLOS ONE relevant to journalists, bloggers and press officers, including details of our press release process and our embargo policy, see the everyONE blog at http://everyone.